PubMed Health⌕ Search

PubMed · 9929426

Parameter Estimation for the Constant Capacitance Surface Complexation Model: Analysis of Parameter Interdependencies.

Abstract

Results of extensive application of the 2-pK constant capacitance surface complexation model (CCM) to surface charge data of a range of minerals in 0.1 M electrolytes are summarized where the program FITEQL has simultaneously been used to study the interdependence of the involved optimized parameters. To illustrate representative results, surface complexation and goodness of fit parameters are given as a function of the capacitance value (C). For all (ca. 150) tested data sets, one of three patterns is observed, two of which do not allow a unique parameter set to be obtained. The results indicate that the optimized site density parameter is relatively insensitive to a wide variation of C; optimized site density is rather low in this range of (higher) C and tends toward maximum proton uptake in the respective data set which in turn will be close to sometimes experimentally observed saturation levels. At low and with further decreasing C a steep increase of site density may occur; in this case, DeltapKa strongly increases after a DeltapKa minimum. Alternatively at low C, DeltapKa may continue to decrease and site density decreases simultaneously after a site density maximum. The observed patterns can be explained by the constraint of C on the electrostatic correction factor. Linear correlation coefficients (which are very useful parameters but do not receive much attention) show that in the region of low C, the optimized parameters become fully correlated, which finally causes nonconvergence in parameter optimization. In the region where the optimized site density is not significantly affected by a decrease in C the optimized parameters are more weakly correlated. When site concentration is co-optimized high correlation between adjustable parameters suggests that it is preferable to have an estimate for this parameter. Overall, it can be stated that substantial difficulties were observed in the effort to obtain unique (and thus meaningful) parameters for the CCM in about 60% of the data sets treated. Copyright 1999 Academic Press.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

J Lützenkirchen. 1999-02-15. Parameter Estimation for the Constant Capacitance Surface Complexation Model: Analysis of Parameter Interdependencies.. https://doi.org/10.1006/jcis.1998.5956

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗